NETRIS Pharma: Funding, Investors & Team (Sep 2026)
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry. The dependence receptors are trans-membrane proteins that receive signals and transmit them inside cells and this helps in controlling tumor development. The company provides vitro and in vivo research, preclinical practices for manufacturing drugs for the treatment of breast cancer, lung cancer, glioblastoma and neuroblastoma cancer.
NETRIS Pharma has raised $8.4M across 1 funding round on record, the most recent an undisclosed round of $8.4M announced in May 2026.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NETRIS Pharma Company Profile and Key Stats
Latest funding round on record: May 2026.
NETRIS Pharma Funding Rounds
NETRIS Pharma Founders and Leadership Team
Contact details for the NETRIS Pharma team: 1 has a LinkedIn profile.
Start 14-day free trial →NETRIS Pharma Funding Compared to Other Biotechnology Startups
NETRIS Pharma's latest round of $8.4M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NETRIS Pharma in Biotechnology and Lyon
Companies Similar to NETRIS Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to…
NETRIS Pharma Funding FAQs
What does NETRIS Pharma do?
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry. The dependence receptors are trans-membrane proteins that receive signals and transmit them inside cells and this helps in controlling tumor development. The company provides vitro and in vivo research, preclinical practices for manufacturing drugs for the treatment of breast cancer, lung cancer, glioblastoma and neuroblastoma cancer.
How much funding has NETRIS Pharma raised?
NETRIS Pharma has raised $8.4M across 1 round on record. The most recent is an undisclosed round of $8.4M announced in May 2026.
When did NETRIS Pharma last raise funding?
NETRIS Pharma's most recent funding round on record is an undisclosed round of $8.4M, announced in May 2026.
Who founded NETRIS Pharma?
FundedIQ lists Patrick Mehlen (Founder) at NETRIS Pharma.
Where is NETRIS Pharma headquartered?
NETRIS Pharma is based in Lyon, Rhone-Alpes, France.
How many employees does NETRIS Pharma have?
NETRIS Pharma is in the 11-50 employee band.
How does NETRIS Pharma's funding compare to other Biotechnology startups?
NETRIS Pharma's latest round of $8.4M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NETRIS Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NETRIS Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.